从风湿病学卓越网络中产生真实世界的证据。

IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY Pharmacoepidemiology and Drug Safety Pub Date : 2024-12-01 DOI:10.1002/pds.70067
Timothy Beukelman, Amy Mudano, Patrick Stewart, Shilpa Venkatachalam, Fenglong Xie, Michael George, Howard Busch, Priya Reddy, Kenneth G Saag, Yujie Su, Jeffrey R Curtis
{"title":"从风湿病学卓越网络中产生真实世界的证据。","authors":"Timothy Beukelman, Amy Mudano, Patrick Stewart, Shilpa Venkatachalam, Fenglong Xie, Michael George, Howard Busch, Priya Reddy, Kenneth G Saag, Yujie Su, Jeffrey R Curtis","doi":"10.1002/pds.70067","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The Excellence Network in RheumatoloGY (ENRGY) was founded in 2021 and encompasses data from more than 700 private practice rheumatology providers throughout the United States, forming a practice-based research network (PBRN).</p><p><strong>Methods: </strong>Electronic health record (EHR) data from participating practices are aggregated, including structured data (e.g., clinical assessments) and unstructured data from two different EHR platforms. Targeted data quality efforts ensure capture of high-quality clinical data and reduce missingness. ENRGY network membership also provides participating sites access to technology services that enhance patient care. Centralized ethics approval and pre-existing legal agreements along with electronic tools to curate data and contact eligible study participants improves efficiency of multi-center prospective studies.</p><p><strong>Results: </strong>The ENRGY data warehouse includes linked administrative claims data for commercial and government-provided insurance (31% of patients linked to commercial claims) and patient-generated health data from both in-office and out-of-office settings via a smartphone app as well as biosensor data. ENRGY data and infrastructure can be employed to identify the highest yield sites for prospective studies; identify patients meeting study eligibility criteria; pre-screen individual patient's willingness to participate in specific studies; centralize study data monitoring; and assist in the conduct of prospective studies.</p><p><strong>Conclusion: </strong>ENRGY data have been used to generate a growing number of scientific publications and may serve as a model for PBRNs in other specialties seeking to harness the potential of data linkages, patient-generated data capture, and centralized study infrastructure for observational and interventional research.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"33 12","pages":"e70067"},"PeriodicalIF":2.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Generating Real-World Evidence From the Excellence Network in Rheumatology.\",\"authors\":\"Timothy Beukelman, Amy Mudano, Patrick Stewart, Shilpa Venkatachalam, Fenglong Xie, Michael George, Howard Busch, Priya Reddy, Kenneth G Saag, Yujie Su, Jeffrey R Curtis\",\"doi\":\"10.1002/pds.70067\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The Excellence Network in RheumatoloGY (ENRGY) was founded in 2021 and encompasses data from more than 700 private practice rheumatology providers throughout the United States, forming a practice-based research network (PBRN).</p><p><strong>Methods: </strong>Electronic health record (EHR) data from participating practices are aggregated, including structured data (e.g., clinical assessments) and unstructured data from two different EHR platforms. Targeted data quality efforts ensure capture of high-quality clinical data and reduce missingness. ENRGY network membership also provides participating sites access to technology services that enhance patient care. Centralized ethics approval and pre-existing legal agreements along with electronic tools to curate data and contact eligible study participants improves efficiency of multi-center prospective studies.</p><p><strong>Results: </strong>The ENRGY data warehouse includes linked administrative claims data for commercial and government-provided insurance (31% of patients linked to commercial claims) and patient-generated health data from both in-office and out-of-office settings via a smartphone app as well as biosensor data. ENRGY data and infrastructure can be employed to identify the highest yield sites for prospective studies; identify patients meeting study eligibility criteria; pre-screen individual patient's willingness to participate in specific studies; centralize study data monitoring; and assist in the conduct of prospective studies.</p><p><strong>Conclusion: </strong>ENRGY data have been used to generate a growing number of scientific publications and may serve as a model for PBRNs in other specialties seeking to harness the potential of data linkages, patient-generated data capture, and centralized study infrastructure for observational and interventional research.</p>\",\"PeriodicalId\":19782,\"journal\":{\"name\":\"Pharmacoepidemiology and Drug Safety\",\"volume\":\"33 12\",\"pages\":\"e70067\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmacoepidemiology and Drug Safety\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pds.70067\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70067","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

目的:风湿病卓越网络(energy)成立于2021年,涵盖了来自美国700多家私人风湿病诊所的数据,形成了一个基于实践的研究网络(PBRN)。方法:汇总来自参与实践的电子健康记录(EHR)数据,包括结构化数据(如临床评估)和来自两个不同EHR平台的非结构化数据。有针对性的数据质量工作确保捕获高质量的临床数据并减少丢失。能源网络的会员资格也为参与的网站提供了获得技术服务的机会,从而提高患者的护理水平。集中的伦理审批和预先存在的法律协议,以及电子工具来管理数据和联系合格的研究参与者,提高了多中心前瞻性研究的效率。结果:energy数据仓库包括与商业和政府提供的保险相关的行政索赔数据(31%的患者与商业索赔相关),以及通过智能手机应用程序和生物传感器数据从办公室和办公室外的设置中生成的患者健康数据。能源数据和基础设施可用于确定前瞻性研究的最高产量地点;确定符合研究资格标准的患者;预筛选个体患者参与特定研究的意愿;集中监测研究数据;并协助进行前瞻性研究。结论:能源数据已被用于产生越来越多的科学出版物,并可作为其他专业pbrn寻求利用数据链接、患者生成数据捕获和集中研究基础设施进行观察和介入性研究的潜力的模型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Generating Real-World Evidence From the Excellence Network in Rheumatology.

Purpose: The Excellence Network in RheumatoloGY (ENRGY) was founded in 2021 and encompasses data from more than 700 private practice rheumatology providers throughout the United States, forming a practice-based research network (PBRN).

Methods: Electronic health record (EHR) data from participating practices are aggregated, including structured data (e.g., clinical assessments) and unstructured data from two different EHR platforms. Targeted data quality efforts ensure capture of high-quality clinical data and reduce missingness. ENRGY network membership also provides participating sites access to technology services that enhance patient care. Centralized ethics approval and pre-existing legal agreements along with electronic tools to curate data and contact eligible study participants improves efficiency of multi-center prospective studies.

Results: The ENRGY data warehouse includes linked administrative claims data for commercial and government-provided insurance (31% of patients linked to commercial claims) and patient-generated health data from both in-office and out-of-office settings via a smartphone app as well as biosensor data. ENRGY data and infrastructure can be employed to identify the highest yield sites for prospective studies; identify patients meeting study eligibility criteria; pre-screen individual patient's willingness to participate in specific studies; centralize study data monitoring; and assist in the conduct of prospective studies.

Conclusion: ENRGY data have been used to generate a growing number of scientific publications and may serve as a model for PBRNs in other specialties seeking to harness the potential of data linkages, patient-generated data capture, and centralized study infrastructure for observational and interventional research.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
相关文献
二甲双胍通过HDAC6和FoxO3a转录调控肌肉生长抑制素诱导肌肉萎缩
IF 8.9 1区 医学Journal of Cachexia, Sarcopenia and MusclePub Date : 2021-11-02 DOI: 10.1002/jcsm.12833
Min Ju Kang, Ji Wook Moon, Jung Ok Lee, Ji Hae Kim, Eun Jeong Jung, Su Jin Kim, Joo Yeon Oh, Sang Woo Wu, Pu Reum Lee, Sun Hwa Park, Hyeon Soo Kim
具有疾病敏感单倍型的非亲属供体脐带血移植后的1型糖尿病
IF 3.2 3区 医学Journal of Diabetes InvestigationPub Date : 2022-11-02 DOI: 10.1111/jdi.13939
Kensuke Matsumoto, Taisuke Matsuyama, Ritsu Sumiyoshi, Matsuo Takuji, Tadashi Yamamoto, Ryosuke Shirasaki, Haruko Tashiro
封面:蛋白质组学分析确定IRSp53和fastin是PRV输出和直接细胞-细胞传播的关键
IF 3.4 4区 生物学ProteomicsPub Date : 2019-12-02 DOI: 10.1002/pmic.201970201
Fei-Long Yu, Huan Miao, Jinjin Xia, Fan Jia, Huadong Wang, Fuqiang Xu, Lin Guo
来源期刊
CiteScore
4.80
自引率
7.70%
发文量
173
审稿时长
3 months
期刊介绍: The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
期刊最新文献
Development of a Pregnancy Cohort in Commercial Insurance Claims Data: Evaluation of Deliveries Identified From Inpatient Versus Outpatient Claims. Development of an Adverse Event Reporting Form for Herbal Medicine: A Delphi Expert Consensus Study. Regulatory Risk Communication on Thrombosis With Thrombocytopenia Syndrome for COVID-19 Adenovirus Vector Vaccines: Comment. Ten Must-Read Papers on Transparency and Reproducibility in Pharmacoepidemiology. Validation of Chronic Inflammatory Demyelinating Polyradiculoneuropathy Coding in US Claims Data.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1